

Available online at www.sciencedirect.com



Biochemical Pharmacology

Biochemical Pharmacology 65 (2003) 989–994 Short communication

www.elsevier.com/locate/biochempharm

Expression of acetoacetyl-CoA synthetase, a novel cytosolic ketone body-utilizing enzyme, in human brain

Masahiro Ohgami, Noriko Takahashi, Masahiro Yamasaki, Tetsuya Fukui*

Department of Health Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan Received 27 September 2002; accepted 28 November 2002

Abstract

Acetoacetyl-CoA synthetase (AACS, acetoacetate-CoA ligase, EC 6.2.1.16) is a ketone body-utilizing enzyme, the physiological role of which remains unclear yet in mammals, particularly has never been studied in human. In order to investigate the tissue distribution of AACS in human, cDNA encoding AACS was isolated from HepG2 cells. Amino acid sequence of human AACS deduced from the open reading frame showed high homology (89.3%) with that of rat AACS and much less homology (43.7%) with that of bacterial AACS. The expression level of the AACS mRNA was high in kidney, heart and brain, but low in liver, and the expression profile of AACS in the human brain was quite similar to that of 3-hydroxy-3-methylglutaryl-CoA reductase.

© 2003 Elsevier Science Inc. All rights reserved.

Keywords: Acetoacetyl-CoA synthetase; Ketone body; Acetoacetate; 3-Hydroxy-3-methylglutaryl-CoA reductase; Tissue distribution; Human

1. Introduction

Acetoacetyl-CoA synthetase (acetoacetate-CoA ligase, EC 6.2.1.16; AACS) is a cytosolic ligase that specifically activates acetoacetate to its coenzyme A ester [1,2]. In bacteria, AACS is known to exhibit important roles in the metabolism of poly-β-hydroxybutyrate, an intracellular reserve of organic carbon and/or chemical energy of some microorganisms [1,3]. While, in mammalian tissues, the physiological role of AACS has not been fully clarified yet compared to the bacterial enzyme, although Endemann et al. have demonstrated that acetoacetate is activated by the action of this enzyme and effectively incorporated into cholesterol and fatty acids in the liver of rat [4]. They proposed that AACS has the function of direct supply of acetyl units from acetoacetate in the cytosol for the synthesis of the lipidic substances and that such cytosolic activation could bypass the pathway involving ATP-citrate

lyase which supplies acetyl units from mitochondria to cytosol [4].

Previously we have shown that the enzyme activity in the liver of rats remarkably increased and then decreased during the animal's development [5] and increased upon the administration of hypocholesterolemic compounds, cholestyramine and/or pravastatin, to rats [6]. Furthermore, we have demonstrated that hepatic AACS specific activity markedly decreased in streptozotocin-induced diabetic rats as in the case of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) or acetyl-CoA carboxylase [7]. These results suggest that direct activation of acetoacetate by AACS in the cytosolic compartment of the cells for cholesterol and/or fatty acids biosynthesis is an important step for the regulation of ketone body utilization and involved in the significant functions in mammals.

In order to clarify the physiological roles of AACS in mammals, we recently cloned the AACS cDNA from the liver of rat fed with hypocholesterolemic agents, and deduced its cDNA-derived amino acid sequence [6]. Since none of the molecular properties, physiological roles or even the presence of AACS in human has been reported before, in the present study we describe the cDNA cloning of human AACS, its molecular characterization and its distribution in the tissues of human.

[™] The nucleotide sequence reported in this paper has been submitted to the DDBJ data base under accession number AB054121.

^{*}Corresponding author. Tel.: +81-3-5498-5771; fax: +81-3-5498-5771. E-mail address: fukui@hoshi.ac.jp (T. Fukui).

Abbreviations: AACS, acetoacetyl-CoA synthetase; SCOT, succinyl-CoA:3-oxoacid CoA-transferase; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase.

2. Materials and methods

2.1. Cloning of human AACS

Human total RNA was prepared from cultured HepG2 cells derived from human hepatocellular carcinoma using Quickprep Total RNA Extraction kit (Amersham Biosciences). This RNA (4 µg) was incubated for 60 min at 37° in the reaction mixture (20 μL) containing 300 units of moloney murine leukemia virus reverse transcriptase (Gibco BRL), 15 units of human placenta RNase inhibitor (WAKO) and 0.5 µg of random hexadeoxynucleotide primer (Takara). To amplify the human AACS cDNA fragment, PCR was performed for 30 cycles in the reaction mixture containing an aliquot of the above cDNA solution, 0.05 units/µL EX Taq DNA polymerase (Takara) and 4 pmol/μL each of sense and antisense degenerate primers representing all possible codons corresponding to the sequences of amino acids 177– 183 (GAIWSST) and 313–318 (KEHVLH), respectively, of rat AACS [6]. Then nested PCR was performed using the above PCR product and sense (185-190, SPDFGVN) and antisense (299–304, CMVHSA) degenerate primers. The amplified DNA of expected size (362 bp) was cloned into the pGEM-T vector (Promega Corporation). The cloned DNA was sequenced with a 377 automated DNA sequencer (PE Applied Biosystems). To determine the entire coding region, the cDNA was analyzed by the rapid amplification of cDNA ends (RACE) method [8].

2.2. Northern blot analysis in tissues of human and various regions of human brain

The membrane blotted human RNA samples (human multiple tissue Northern blots membrane; MTN blots membrane) was purchased from Clontech Corporation. The membrane was prehybridized at 42° for 4 hr in a hybridization solution (10% dextran sulfate, 50% formamide, 2% SDS, $5 \times$ SSPE, $5 \times$ Denhardt's solution, 100 µg/mL heatdenatured salmon sperm DNA), followed by hybridization at 42° for 18 hr in the hybridization solution containing a ³²P-labeled probe encoding human AACS or human HMGCR [9] labeled by Ready-To-Go DNA Labeling Beads (Amersham Biosciences) with cytidine 5'-α-[³²P] dCTP (~30 TBq/mmol, Amersham Biosciences). The membrane was then washed at room temperature three times for 5 min each time in $2 \times SSC/0.1\%$ SDS, and at 65° twice for 30 min each time in $0.25 \times SSC/0.1\%$ SDS. The washed membrane was analyzed with a radioimaging analyzer (BAS2000, Fuji Photo Film).

3. Results and discussion

3.1. cDNA for human AACS

Fig. 1 shows the isolated cDNA for human AACS. The restriction map of cDNA for human AACS is shown in

Fig. 1a. It is our understanding that so far nucleotide sequence of a cDNA coding AACS has been published for rat liver [6] and *Sinorhizobium meliloti*, a poly-β-hydroxybutyrate-accumulating bacterium [3]. The coding region for the human AACS was composed of 2016 bp (672 amino acid residues) with a calculated molecular weight of 75,143 (Fig. 1b). This nucleotide length was identical to that of rat AACS cDNA, of which calculated molecular weight was 75,039 [6]. While, nucleotide length of the microbial cDNA (1950 bp, 650 amino acid residues) and calculated molecular weight (71,370) [3] were considerably different from those for animals.

3.2. Homology of AACS between human, rat and bacteria

The amino acid sequence of human AACS deduced from the open reading frame showed high homology (89.3%) with that of rat enzyme [6] and much less homology (43.7%) with that of *S. meliloti* enzyme [3]. Homology alignments of three AACSs are shown in Fig. 2. Amino acid sequences of AACSs have AMP-binding motifs ([LIVMFY]-x(2)-[STG]-[STAG]-G-[ST]-[STEI]-[SG]-x-[PASLIVM]-[KR]) in the same region (human and rat AACSs, I287-K298; *S. meliloti* I268-K279). This motif is known to be present in a number of prokaryotic and eukaryotic enzymes which act *via* an ATP-dependent covalent binding of AMP to their substrate [10,11].

These enzymes also share a region of methionine- and tryptophan-rich sequence in the same region (human and rat AACSs, 335–341, WMMWNWM; *S. meliloti* 316–321, WMMWNW). Since a similar sequence was also found in microbial acetyl-CoA synthetases [6,12], this sequence was searched in BLAST protein sequence database. It turned out that this unique sequence is only observed in those of AACSs and acetyl-CoA synthetases. Since methionine and tryptophan are rarely distributed amino acids in common protein sequence, it is possible that this region plays an important role for the function related to the activation of short chain fatty acids.

3.3. Tissue distribution of AACS

In nonhepatic tissues of mammals, acetoacetate is known to be activated to its CoA ester by mitochondrial succinyl-CoA:3-oxoacid CoA-transferase (EC 2.8.3.5; SCOT) and regarded to be mainly used for energy source in mitochondria [13,14]. On the other hand, in the cytosol of lipogenic tissues of the rat, acetoacetate is demonstrated to be activated by the action of AACS for the synthesis of cholesterol and fatty acids [4]. In order to investigate physiological roles of human AACS, tissue distribution of the human enzyme was examined by Northern blot analysis with a ³²P-labeled human AACS cDNA probe (2176 bp portion; nucleotides –107 to 2069 in Fig. 1) using human MTN blots. As shown in Fig. 3, expression of AACS was detected in various tissues of human. Interestingly, expression level

1.5

2.0

2.5 kbp

1.0




Fig. 1. Structure of human AACS cDNA. (a) Restriction map of the cDNA. The solid box represents the open reading frame. (b) Nucleotide sequence of the human AACS cDNA and the predicted amino acid sequence of the protein.

of the enzyme was highest in kidney, and the level in heart was also as high as in brain, but that in liver was much lower. It was reported that the activity and immunologically determined level of the enzyme in the rat was high in the lipogenic tissues, such as liver, brain and adipose tissue, but considerably low in kidney and heart [15]. To our knowl-

(a)

0

0.5

edge, up to the present there is no information on the physiological roles of AACS in kidney and heart of animals, and on the difference in the tissue distribution of the enzyme between human and rat, so that, this is the first report on the demonstration of AACS in human and AACS mRNA levels in animal tissues.




Fig. 2. Homology alignments of AACSs of rat and *Sinorhizobium meliloti* (indicated as Sm). Boxes indicate identical amino acid residues of the sequences. Underlines indicate the sequence specific to AACS and acetyl-CoA synthetase, or the sequence for AMP-binding site.

As to the ketone body metabolism in kidney and heart, Marcondes *et al.* reported that catalytic activity of renal SCOT was impaired by the administration of endotoxin to rats and that this impairment was accompanied by SCOT tyrosine nitration [16]. They also demonstrated such decrease in the catalytic activity and tyrosine nitration of SCOT in the heart of streptozotocin-induced diabetic rats and suggested that the impairment of the ketone body-

utilizing enzyme is a contributing factor to the derangements in myocardial substrate utilization in the diabetic status [17]. We previously showed that specific activity of AACS markedly decreased in the liver of streptozotocin-induced diabetic rats correspondingly to the immunologically determined protein level of AACS [7]. Thus, although the regulatory mechanism of AACS activity seems to be different from that of SCOT activity, the high expression of




Fig. 3. Expression of AACS mRNA in various tissues of human. Northern blot analysis was carried out with the ³²P-labeled human AACS cDNA probe using human multiple tissue Northern blots as described in Section 2. The radioactivity was quantified as photostimulated luminescence (PSL, Fuji BAS system) for each band.

human AACS observed in the kidney and heart indicates the possibility that the enzyme is also involved in the important parts of the cellular functions of human, even in the tissues different from the lipogenic ones, including the production of energy source from the ketone body, which has been regarded as the specific role of SCOT in mammals.

3.4. Expression profiles of AACS and HMGCR in human brain

The high expression of AACS in the human brain (Fig. 3) led us to the investigation of AACS distribution in the various regions of the brain using human MTN blots. As shown in Fig. 4, there were high levels of expression of AACS in hippocampus, amygdala and thalamus, and the expression profile of AACS in the human brain was quite similar to that of HMGCR, the rate-limiting enzyme of cholesterol biosynthesis. Recently much attention has been focused on the relationship between cholesterol metabolism and Alzheimer disease [18]. Michikawa and Yanagisawa reported that viability of neurons, different from that of nonneuronal cells, depends on the intracellular cholesterol content [19]. Furthermore, it was indicated that there is a lower prevalence of diagnosed probable Alzheimer disease in patients taking the HMGCR inhibitors (statins) [20,21]. As to an action of ketone body on neurons, Kashiwaya et al. recently demonstrated that




Fig. 4. Expression of AACS and HMGCR mRNAs in various regions of human brain. Northern blot analysis was carried out with the ³²P-labeled human AACS (upper) or HMGCR (lower) cDNA probe using human multiple tissue Northern blots as described in Section 2. The radioactivity was quantified as photostimulated luminescence (PSL, Fuji BAS system) for each band.

D-β-hydroxybutyrate protects cultured rat hippocampal cells from the toxicity of a fragment of amyloid protein, $A\beta_{1-42}$ [22]. Taken together of the role of AACS in the ketone body utilization to supply acetyl units directly from acetoacetate in the cytosolic compartment for the cholesterol biosynthesis [4] and our results of the quite similar expression profiles between AACS and HMGCR in human brain, it is possible that regulation of AACS activity is one of the important targets for the study on the Alzheimer disease.

Acknowledgments

This work was supported in part by grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References

- Fukui T, Ito M, Tomita K. Purification and characterization of acetoacetyl-CoA synthetase from *Zoogloea ramigera* I-16-M. Eur J Biochem 1982;127:423-8.
- [2] Ito M, Fukui T, Kamokari M, Saito T, Tomita K. Purification and characterization of acetoacetyl-CoA synthetase from rat liver. Biochim Biophys Acta 1984;794:183–93.
- [3] Cai GQ, Driscoll BT, Charles TC. Requirement for the enzymes acetoacetyl coenzyme A synthetase and poly-3-hydroxybutyrate (PHB) synthase for growth of *Sinorhizobium meliloti* on PHB cycle intermediates. J Bacteriol 2000:182:2113–8.
- [4] Endemann G, Goetz PG, Edmond J, Brunengraber H. Lipogenesis from ketone bodies in the isolated perfused rat liver. Evidence for the cytosolic activation of acetoacetate. J Biol Chem 1982;257:3434–40.
- [5] Nakamoto M, Takahashi N, Iwahori A, Sato H, Fukui T. Effects of development on acetoacetyl-CoA synthesis biosynthesis in rat liver. Biol Pharm Bull 1999;22:981–3.
- [6] Iwahori A, Takahashi N, Nakamoto M, Iwama M, Fukui T. cDNAderived amino acid sequence of acetoacetyl-CoA synthetase from rat liver. FEBS Lett 2000;466:239–43.
- [7] Sato H, Takahashi N, Nakamoto M, Ohgami M, Yamazaki M, Fukui T. Effects of streptozotocin-induced diabetes on acetoacetyl-CoA synthetase activity in rats. Biochem Pharmacol 2002;63:1851–5.
- [8] Frohman MA, Dush MK, Martin GR. Rapid production of full-length cDNAs from rare transcripts: amplification using a single genespecific oligonucleotide primer. Proc Natl Acad Sci USA 1988; 85:8998–9002.
- [9] Luskey KL, Stevens B. Human 3-hydroxy-3-methylglutaryl coenzyme A reductase. Conserved domains responsible for catalytic activity and sterol-regulated degradation. J Biol Chem 1985;260: 10271-7.
- [10] Conti E, Franks NP, Brick P. Crystal structure of firefly luciferase throws light on a superfamily of adenylate-forming enzymes. Structure 1996;4:287–98.
- [11] Babbitt PC, Kenyon GL, Martin BM, Charest H, Slyvestre M, Scholten JD, Chang KH, Liang PH, Dunaway-Mariano D. Ancestry of the 4-chlorobenzoate dehalogenase: analysis of amino acid sequence identities among families of acyl:adenyl ligases, enoyl-CoA hydratases/isomerases, and acyl-CoA thioesterases. Biochemistry 1992; 31:5594–604.

- [12] Klenk HP, Clayton RA, Tomb JF, White O, Nelson KE, Ketchum KA, Dodson RJ, Gwinn M, Hickey EK, Peterson JD, Richardson DL, Kerlavage AR, Graham DE, Kyrpides NC, Fleischmann RD, Quackenbush J, Lee NH, Sutton GG, Gill S, Kirkness EF, Dougherty BA, McKenney K, Adams MD, Loftus B, Peterson S, Reich CI, McNeil LK, Badger JH, Glodek A, Zhou L, Overbeek R, Gocayne JD, Weidman JF, McDonald L, Utterback T, Cotton MD, Spriggs T, Artiach P, Kaine BP, Sykes SM, Sadow PW, D'Andrea KP, Bowman C, Fujii C, Garland SA, Mason TM, Olsen GJ, Fraser CM, Smith HO, Woese CR, Venter JC. The complete genome sequence of the hyperthermophilic, sulphate-reducing archaeon *Archaeoglobus fulgidus*. Nature 1997;390:364–70.
- [13] Tildon JT, Sevdalian DA. CoA transferase in the brain and other mammalian tissues. Arch Biochem Biophys 1972;148:382–90.
- [14] Robinson AM, Williamson DH. Physiological roles of ketone bodies as substrates and signals in mammalian tissues. Physiol Rev 1980;60:143–87.
- [15] Ito M, Fukui T, Saito T, Tomita K. Acetoacetyl-CoA synthetase specific activity and concentration in rat tissues. Biochim Biophys Acta 1986:876:280-7.
- [16] Marcondes S, Turko IV, Murad F. Nitration of succinyl-CoA:3-ox-oacid CoA-transferase in rats after endotoxin administration. Proc Natl Acad Sci USA 2001;98:7146–51.
- [17] Turko IV, Marcondes S, Murad F. Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA:3-oxoacid CoA-transferase. Am J Physiol Heart Circ Physiol 2001;281:H2289–94.
- [18] Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 1995;45:1092–6.
- [19] Michikawa M, Yanagisawa K. Inhibition of cholesterol production but not of nonsterol isoprenoid products induces neuronal cell death. J Neurochem 1999;72:2278–85.
- [20] Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000;356:1627–31.
- [21] Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57: 1439–43.
- [22] Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K, Veech RL. D-Beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc Natl Acad Sci USA 2000;97:5440–4.